AMRI Appoints Director of Global Project Management

AMRI (NASDAQ: AMRI) has named Michael D. Ironside, Ph.D. as director of global project management reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing.

In this newly created role, Dr. Ironside will be responsible for overseeing all project management activities related to products moving through AMRI’s pharmaceutical services organization.

Dr. Ironside brings over 18 years of experience in the pharmaceutical industry. Most recently, he served in a consultant role as president of Rondaxe Scientific Solutions. Before joining Rondaxe, he was chief scientific officer at Biosignal, an emerging biotech company in Australia. Dr. Ironside also brings over 8 years of significant prior relevant AMRI experience, joining the company in 1998 as a section head in chemical development and subsequently assuming increased levels of responsibility culminating in the oversight and leadership of AMRI’s chemical development and small scale cGMP (current Good Manufacturing Practice) unit.

Dr. Ironside holds a Ph.D. in organic chemistry from Dundee University in Scotland and was a postdoctoral fellow at Sydney University in Australia.

AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, "Dr. Ironside’s significant experience in project management and customer relations activities, in addition to his hands-on knowledge of the AMRI organization, make him an immediately value-added member of our organization. As we continue to grow in the area of manufacturing services, the ability to seamlessly manage projects across the pharmaceutical development spectrum adds value to our customers through enhancement of knowledge transfer, elevated level of quality and shorter time to deliver.”

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, delay or denial of approvals from the FDA, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission on March 17, 2008 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.